Year |
Citation |
Score |
2022 |
Anderson KG, Oda SK, Bates BM, Burnett MG, Rodgers Suarez M, Ruskin SL, Greenberg PD. Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy. Journal For Immunotherapy of Cancer. 10. PMID 35264436 DOI: 10.1136/jitc-2021-003959 |
0.455 |
|
2020 |
Oda SK, Anderson KG, Ravikumar P, Bonson P, Garcia NM, Jenkins CM, Zhuang S, Daman AW, Chiu EY, Bates BM, Greenberg PD. A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy. The Journal of Experimental Medicine. 217. PMID 32860705 DOI: 10.1084/Jem.20191166 |
0.533 |
|
2019 |
Anderson KG, Voillet V, Bates B, Chiu EY, Burnett MG, Garcia NM, Oda SK, Morse CB, Stromnes IM, Drescher CW, Gottardo R, Greenberg PD. Engineered adoptive T-cell therapy prolongs survival in a preclinical model of advanced stage ovarian cancer. Cancer Immunology Research. PMID 31337659 DOI: 10.1158/2326-6066.Cir-19-0258 |
0.455 |
|
2019 |
Anderson KG, Egan D, Hingorani SR, Oda SK, Paulson K, Perret R, Schmidt L, Schmitt T, Stromnes I, Chapuis A, Greenberg PD. Abstract IA17: Utilizing synthetic biology and high-dimensional probing to address therapeutic obstacles and empower engineered T cells with the capacity to eradicate tumors Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Ia17 |
0.523 |
|
2019 |
Greenberg PD, Anderson KG, Egan D, Hingorani SR, Nezi L, Manzo T, Oda SK, Paulson KG, Perret R, Schmidt L, Schmitt TM, Stromnes IM, Chapuis AG. Abstract I11: Targeting pancreatic cancer with TCR-engineered T cells Immunology. 79. DOI: 10.1158/1538-7445.Panca19-I11 |
0.41 |
|
2018 |
Greenberg PD, Anderson KG, Egan D, Hingorani SR, Oda SK, Perret R, Schmitt TM, Stromnes IM, Schmidt L, Chapuis AG. Abstract IA02: Engineering T cells to eradicate tumors in the age of synthetic biology Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-Ia02 |
0.584 |
|
2018 |
Anderson K, Oda S, Bates B, Chiu E, Morse C, Garcia N, Greenberg P. Abstract 2555: Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in solid tumors Cancer Research. 78: 2555-2555. DOI: 10.1158/1538-7445.Am2018-2555 |
0.506 |
|
2017 |
Oda SK, Daman AW, Garcia NM, Wagener F, Schmitt TM, Tan X, Chapuis AG, Greenberg PD. A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T cell function and therapy of murine leukemia. Blood. PMID 29042364 DOI: 10.1182/Blood-2017-04-777052 |
0.574 |
|
2017 |
Greenberg PD, Chapuis A, Egan D, Stromnes I, Hingorani S, Oda S, Perret R, Anderson K, Schmitt T. Abstract IA18: Building better T cells for targeting and eliminating tumors Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-Ia18 |
0.494 |
|
2016 |
Greenberg PD, Anderson KG, Egan D, Hingorani SR, Oda SK, Perret R, Schietinger A, Schmitt TM, Stromnes IM, Wilkens A, Chapuis AG. Abstract IA01: Engineering T cell responses to tumors: Taking the immune system where no responses have gone before Cancer Immunology Research. 4. DOI: 10.1158/2326-6066.Imm2016-Ia01 |
0.535 |
|
2014 |
Hu J, Oda SK, Shotts K, Donovan EE, Strauch P, Pujanauski LM, Victorino F, Al-Shami A, Fujiwara Y, Tigyi G, Oravecz T, Pelanda R, Torres RM. Lysophosphatidic acid receptor 5 inhibits B cell antigen receptor signaling and antibody response. Journal of Immunology (Baltimore, Md. : 1950). 193: 85-95. PMID 24890721 DOI: 10.4049/Jimmunol.1300429 |
0.327 |
|
2014 |
Mourich DV, Oda SK, Schnell FJ, Crumley SL, Hauck LL, Moentenich CA, Marshall NB, Hinrichs DJ, Iversen PL. Alternative splice forms of CTLA-4 induced by antisense mediated splice-switching influences autoimmune diabetes susceptibility in NOD mice. Nucleic Acid Therapeutics. 24: 114-26. PMID 24494586 DOI: 10.1089/nat.2013.0449 |
0.32 |
|
2013 |
Oda SK, Strauch P, Fujiwara Y, Al-Shami A, Oravecz T, Tigyi G, Pelanda R, Torres RM. Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression. Cancer Immunology Research. 1: 245-55. PMID 24455753 DOI: 10.1158/2326-6066.Cir-13-0043-T |
0.691 |
|
2009 |
Kerkvliet NI, Steppan LB, Vorachek W, Oda S, Farrer D, Wong CP, Pham D, Mourich DV. Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. Immunotherapy. 1: 539-47. PMID 20174617 DOI: 10.2217/Imt.09.24 |
0.491 |
|
2007 |
Marshall NB, Oda SK, London CA, Moulton HM, Iversen PL, Kerkvliet NI, Mourich DV. Arginine-rich cell-penetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing. Journal of Immunological Methods. 325: 114-26. PMID 17673254 DOI: 10.1016/J.Jim.2007.06.009 |
0.397 |
|
Show low-probability matches. |